Gene Therapy Competitive landscape Report 2023: Analysis of Pipeline drugs, therapies and treatment by DelveInsight

Gene Therapy Competitive landscape Report 2023: Analysis of Pipeline drugs, therapies and treatment by DelveInsight
Gene Therapy Competitive landscape

Gene Therapy pipeline constitutes 250+ key companies continuously working towards Developing 300+ Gene Therapy treatment therapies, analyses DelveInsight

 

Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, gene therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g. hemophilia and sickle cell disease) and acquired disorders (e.g. leukemia) have been treated with gene therapy.

 

DelveInsight’s, “Gene Therapy Competitive landscape, 2023,” report provides comprehensive insights about 250+ companies and Gene Therapy drugs in Gene Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the Gene Therapy Competitive landscape report, click here: Gene Therapy Competitive Report

 

Key Takeaways from the Gene Therapy Competitive landscape report:

  • Leading Gene Therapy Companies working in the market are Novartis, Johnson&Johnson, Fibrocell Technologies, Pfizer, Sarepta Therapeutics, REGENXBIO, Solid Biosciences Inc., Lexeo Therapeutics, Spark Therapeutics, Xalud Therapeutics, uniQure, Ultragenyx Pharmaceutical, Nanoscope Therapeutics, Homology Medicines, Freeline Therapeutics, Amicus Therapeutics, CSL, Gyroscope Therapeutics, Sangamo Therapeutics, Spark therapeutics, LYSOGENE, Asklepios BioPharmaceutical, Alcyone Therapeutics, Taysha Gene Therapies, Gensight Biologic and Others.
  • Key Gene therapies for treatment in various stages of development include Etranacogene dezaparvovec, Engensis, Fordadistrogene movaparvovec, RGX-121, LYS-SAF302, GT005, SPK 3006, FLT190, LX2006 and Others.
  • In March 2022, REGENXBIO, announced that the US Food and Drug Administration granted Rare Pediatric Disease Designation for RGX-202, which may entitle REGENXBIO to receive a priority review voucher which can be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred should a new BLA for RGX-202 be approved.

 

DelveInsight’s Gene Therapy Report covers around 300+ products under different phases of clinical development like

  • Assessment by Gene Therapy Product Type
  • Assessment by Stage and Product Type of Gene Therapy
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of Gene Therapy
  • Assessment by Gene Therapy Molecule Type
  • Assessment by Stage and Molecule Type of Gene Therapy

 

Emerging Gene Therapy Drugs Under Different Phases of Clinical Development Include:

Some of the Gene Therapy therapies are bluebird bio Zynteglo, RGX-121, and Many Others.

 

Further Gene Therapy product details are provided in the report. Download the Gene Therapy Pipeline report to learn more about the emerging Gene Therapy therapies atGene Therapy Clinical trial advancements

 

Key companies in the Gene Therapy Therapeutics Market:

Some of the Gene Therapy Companies working in the market are Novartis, Johnson &Johnson, Fibrocell Technologies, Pfizer, Sarepta Therapeutics, REGENXBIO, Solid Biosciences Inc., Lexeo Therapeutics, Spark Therapeutics, Xalud Therapeutics, uniQure, Ultragenyx Pharmaceutical, Nanoscope Therapeutics, Homology Medicines, Freeline therapeutics, Amicus Therapeutics, CSL, Gyroscope Therapeutics, Sangamo Therapeutics, Spark therapeutics, LYSOGENE, Asklepios BioPharmaceutical, Alcyone Therapeutics, Taysha Gene Therapies, Gensight Biologic and Others.

 

Request for Sample PDF Report to know in detail about the recent developments and advancements in Gene Therapy clinical trialsGene Therapy Treatment Landscape

 

Table of Content (TOC)

1. Gene Therapy Pipeline Report Introduction

2. Gene Therapy Pipeline Report Executive Summary

3. Gene Therapy Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Gene Therapy Clinical Trial Therapeutics

6. Gene Therapy Pipeline: Late Stage Products (Pre-registration)

7. Gene Therapy Pipeline: Late Stage Products (Phase III)

8. Gene Therapy Pipeline: Mid Stage Products (Phase II)

9. Gene Therapy Pipeline: Early Stage Products (Phase I)

10. Gene Therapy Pipeline Therapeutic Assessment

11. Inactive Products in the Gene Therapy Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Gene Therapy Companies

14. Key Products in the Gene Therapy Pipeline

15. Unmet Needs

16. Gene Therapy Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample page Now @ https://www.delveinsight.com/sample-request/gene-therapy-competitive-landscape

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services


Posted

in

by

Tags: